ProCE Banner Activity

Importance of BRCA Testing and the Role of PARP Inhibition in Early Breast Cancer

Slideset Download

Gain perspectives from a multidisciplinary panel of experts as they discuss the importance of and challenges with implementing BRCA testing in patients with early breast cancer and the role of adjuvant PARP inhibition.

Released: February 17, 2023

Expiration: February 16, 2024

Share

Faculty

Constance Albarracin

Constance Albarracin, MD, PhD

Professor
Director, Breast Fellowship Program
University of Texas MD Anderson Cancer Center
Houston, Texas

Banu Arun

Banu Arun, MD

Professor, Breast Medical Oncology
Co-Director, Clinical Cancer Genetics 
Executive Director, Cancer Genetics
MD Anderson Cancer Networks
University of Texas MD Anderson Cancer Center
Houston, Texas

Allison Butts

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

Emilia Diego

Emilia Diego, MD, FACS

Division Chief
Division of Breast Surgery
University of Pittsburgh Medical Center
Co-Director
Division of Breast Surgery
UPMC Hillman Cancer Center Breast Program
Pittsburgh, Pennsylvania

Charles E. Geyer, Jr.

Charles E. Geyer, Jr., MD

Professor of Medicine
Division of Hematology/Medical Oncology
Department of Internal Medicine
University of Pittsburgh UPMC Hillman Cancer Center
Staff Attending
Breast Medical Oncology
UPMC Magee Womens Hospital
Pittsburgh, Pennsylvania

Marissa Marti-Smith

Marissa Marti-Smith, APRN, AGNP-C, AOCNP

Nurse Practitioner
Breast Oncology
Texas Oncology Baylor Sammons Cancer Center
Dallas, Texas

Kristen Shannon

Kristen Shannon, MS, CGC

Director
Mass General Cancer Center Genetics Program
Mass General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

ProCE

ProCE Banner